Table of Contents PART 01: Executive summary PART 02: Scope of  the report PART 03: Research Methodology PART 04: Introduction Key market highlights PART 05: An overview of lifestyle diseases PART 06: Market landscape Market overview Five forces analysis PART 07: Pipeline landscape PART 08: Market segmentation  by therapy area Depression Dermatology (acne, anti-aging, and baldness) Sexual dysfunction Obesity PART 09: Geographical segmentation Lifestyle drugs market in Americas Lifestyle drugs market in EMEA Lifestyle drugs market in APAC PART 10: Market drivers Lifestyle changes Development of novel therapeutics Increasing demand from older population PART 11: Impact of drivers PART 12: Market challenges Patent expiries Side effects coupled with product recalls Presence of alternative therapies and treatments PART 13: Impact of drivers and challenges PART 14: Market trends Increase in M&A Growing focus on development of drugs for new indications Emerging lifestyle diseases PART 15: Vendor landscape Competitive scenario PART 16: Key vendor analysis Allergan BMS Eli Lilly Pfizer Other prominent vendors PART 17: Appendix List of abbreviation PART 18: Explore Technavio List of Exhibits Exhibit 01: Global lifestyle drugs market snapshot Exhibit 02: Global lifestyle drugs market 2016-2021 ($ billions) Exhibit 03: Opportunity analysis in global lifestyle drugs market Exhibit 04: Five forces analysis Exhibit 05: Pipeline analysis of vendors in Phase III Exhibit 06: Key pipeline drugs for depression 2016 Exhibit 07: Key pipeline drugs for dermatology (anti-aging, baldness, and acne) 2016 Exhibit 08: Key pipeline drugs for sexual dysfunction 2016 Exhibit 09: Key pipeline drugs for obesity Exhibit 10: Global depression drugs market 2016-2021 ($ billions) Exhibit 11: Global dermatology lifestyle drugs market 2016-2021 ($ billions) Exhibit 12: Global sexual dysfunction drugs market 2016-2021 ($ billions) Exhibit 13: Global obesity drugs market 2016-2021 ($ billions) Exhibit 14: Segmentation of global lifestyle drugs market by geography 2016 and 2021 Exhibit 15: Global lifestyle drugs market revenue by geography 2016-2021 ($ billions) Exhibit 16: Market scenario in Americas Exhibit 17: Lifestyle drugs market in Americas 2016-2021 ($ billions) Exhibit 18: Market scenario in EMEA Exhibit 19: Lifestyle drugs market in EMEA 2016-2021 ($ billions) Exhibit 20: Market scenario in APAC Exhibit 21: Lifestyle drugs market in APAC 2016-2021 ($ billions) Exhibit 22: Impact of drivers Exhibit 23: Impact of drivers and challenges Exhibit 24: Competitive structure analysis of global lifestyle drugs market 2016 Exhibit 25: Competitive analysis of global lifestyle drugs market Exhibit 26: Market penetration of various lifestyle drug manufacturers worldwide 2016 Exhibit 27: Strategic success factors of companies in global lifestyle drugs market Exhibit 28: Allergan: Key highlights Exhibit 29: Allergan: Strength assessment Exhibit 30: Allergan: Strategy assessment Exhibit 31: Allergan: Opportunity assessment Exhibit 32: BMS: Strength assessment Exhibit 33: BMS: Strategy assessment Exhibit 34: BMS: Opportunity assessment Exhibit 35: BMS: YoY and growth rate of Abilify 2013-2015 ($ billions) Exhibit 36: Eli Lilly: Key highlights Exhibit 37: Eli Lilly: Strength assessment Exhibit 38: Eli Lilly: Strategy assessment Exhibit 39: Eli Lilly: Opportunity assessment Exhibit 40: Eli Lilly: YoY and growth rate of Cymbalta 2013-2015 ($ millions) Exhibit 41: Eli Lilly: YoY and growth rate of Zyprexa 2013-2015 ($ millions) Exhibit 42: Eli Lilly: YoY and growth rate of Strattera 2013-2015 ($ millions) Exhibit 43: Eli Lilly: YoY and growth rate of Cialis 2013-2015 ($ millions) Exhibit 44: Pfizer: Key highlights Exhibit 45: Pfizer: Strength assessment Exhibit 46: Pfizer: Strategy assessment Exhibit 47: Pfizer: Opportunity assessment Exhibit 48: Pfizer: YoY and growth rate of Pristiq 2013-2015 ($ millions) Exhibit 49: Pfizer: YoY and growth rate of Zoloft 2013-2015 ($ millions) Exhibit 50: Pfizer: YoY and growth rate of Effexor 2013-2015 ($ millions) Exhibit 51: Pfizer: YoY and growth rate of Viagra 2013-2015 ($ millions)

Allergan, BMS, Eli Lilly, Pfizer, Acerus Pharmaceuticals, Alkermes, Amorepacific, AndroScience, Anterios, AstraZeneca, Avanir Pharmaceuticals, Avolynt, Celtaxsys, Cerecor, Corcept Therapeutics, Cosmo Pharmaceuticals, CTC Bio, Dermira, Dong-A ST, Euthymics Bioscience, Foamix, Follicum, Forendo Pharma, Futura Medical Developments, Galderma, Hanmi Pharmaceutical, Incyte, Intrepid Therapeutics, Ion Channel Innovations, iX Biopharma, Johnson & Johnson, Legacy Healthcare, LEO Pharma, H. Lundbeck, Luye America Pharmaceuticals, Merck, Minerva Neurosciences, MSI Methylation Sciences, Neuralstem, Novan, Novartis, Novo-Nordisk, Palatin Technologies, Paratek Pharmaceuticals, Photocure, Revance Therapeutics, Rhythm Pharmaceuticals, S1 Biopharma, Sage Therapeutics, Samumed, Sanofi, Sigma-Tau Pharmaceuticals, Strategic Science & Technologies, Sumitomo Dainippon Pharma, Takeda, TetraLogic Pharmaceuticals, TherapeuticsMD, Valeant Pharmaceuticals, VistaGen Therapeutics, VIVUS, XBiotech, Yuhan, Zafgen.